Active stealth and self-positioning biomimetic vehicles achieved effective antitumor therapy.

J Control Release

Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, PR China; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China; Cancer Center of Zhejiang University, Hangzhou 310058, PR China. Electronic address:

Published: July 2021

AI Article Synopsis

  • - Mesenchymal stem cells (MSCs) are considered effective for drug delivery but face challenges with drug capacity and safety; this study introduces MSC membrane-coated mesoporous silica nanoparticles (MSN@M) as a solution.
  • - The integration of MSC membranes onto mesoporous silica nanoparticles improved stealth and reduced clearance by the immune system, allowing for better targeting and drug retention in cancerous tissues.
  • - When tested in mice with tumors, MSN@M demonstrated significantly enhanced drug loading, sustained release of doxorubicin (DOX), and effectively inhibited tumor growth while minimizing side effects, suggesting it could be a promising alternative for antitumor therapies.

Article Abstract

Mesenchymal stem cells (MSCs) are recognized as promising drug delivery vehicles. However, the limitation of drug loading capacity and safety considerations are two obstacles to the further application of MSCs. Here, we report MSC membrane-coated mesoporous silica nanoparticles (MSN@M) that maintain the active stealth and self-positioning drug delivery abilities of MSCs and resolve issues related to MSCs-mediated drug delivery. MSN@M was established through uniformly integrating MSC membrane onto a mesoporous silica nanoparticle (MSN) core by sonication. Reduced clearance of phagocytes mediated by CD47 marker on MSC membrane was observed in vitro, which explained the only ~ 25% clearance rate of MSN@M compared with MSN in vivo within 24 h. MSN@M also showed stronger tumor targeting and penetration ability compared with MSN in HepG2 tumor bearing mice. Simultaneously, MSN@M exhibited strong capacity for drug loading and sustained drug release ability of MSN when loaded with doxorubicin (DOX), the drug loading of MSN@M increased ~ 5 folds compared with MSC membrane. In HepG2 xenograft mice, DOX-loaded MSN@M effectively inhibited the growth of tumors and decreased the side effects of treatment by decreasing the exposure of other tissues to DOX. Consequently, our MSN@M may serve as alternative vehicles for MSCs and provide more options for antitumor treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2021.05.031DOI Listing

Publication Analysis

Top Keywords

drug delivery
12
drug loading
12
msc membrane
12
active stealth
8
stealth self-positioning
8
mesoporous silica
8
msn@m
8
compared msn
8
drug
7
self-positioning biomimetic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!